Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $32.67 and traded as low as $29.67. Agios Pharmaceuticals shares last traded at $30.97, with a volume of 930,895 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AGIO. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday, September 21st. Citigroup increased their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 31st. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Truist Financial reduced their price target on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Agios Pharmaceuticals Trading Down 3.1%

The company has a 50 day moving average of $33.10 and a 200-day moving average of $32.70. The firm has a market capitalization of $1.87 billion, a P/E ratio of -4.47 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the transaction, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGIO. Nykredit A S purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $43,000. Integrated Wealth Concepts LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $47,000. Allworth Financial LP purchased a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $73,000. Finally, Versant Capital Management Inc grew its position in shares of Agios Pharmaceuticals by 378.7% during the 2nd quarter. Versant Capital Management Inc now owns 2,001 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 1,583 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases. Based in Cambridge, Massachusetts, the company specializes in cellular metabolism and the development of therapies designed to address underlying disease biology rather than only treating symptoms.

Agios’ lead commercial product is Pyrukynd (mitapivat), an oral pyruvate kinase activator approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.